Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
about
Silymarin for HCV infectionComparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study.In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitisPathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trialAn assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals.Evolution of New Variants/Mutants of JE Virus, Its Effect on Neurovirulence, Antigenicity, Host Immune Responses and Disease Transmission in Endemic Areas
P2860
Q26851453-0580821D-8F36-4FBF-9F75-E31862A0F1FBQ33793287-F1DBFFF2-42C4-4E8F-967D-45F7A3248490Q34727822-8A32D08A-5C28-4A79-861F-11C4A321B680Q35619104-B7C88DE0-B071-4FCB-B23D-0CB672DA9636Q36933129-F8B1277E-2767-4B8F-8BB6-B9353885449BQ37422723-CA1BB199-713A-4D0E-8493-282347B63F74Q41729153-07A2D391-38C4-4F5D-A3EC-208A7A894BB9Q55510566-114AF550-62BC-4560-9BE5-7D8A2C7143F7Q59049769-DB2F0DB6-BB6D-4285-97EB-C4000438FE45
P2860
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@ast
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@en
type
label
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@ast
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@en
prefLabel
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@ast
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@en
P2093
P2860
P50
P356
P1433
P1476
Rationale, challenges, and par ...... roduct for chronic hepatitis C
@en
P2093
Catherine M Meyers
Edward Doo
Michael W Fried
Roy L Hawke
Steven H Belle
SyNCH Study Group
Victor J Navarro
P2860
P304
P356
10.1177/1740774511427064
P577
2011-11-04T00:00:00Z